Pharmac is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat moderate to severe cases of COVID-19, subject to access criteria from 1 October 2021
Pharmac is considering awarding principal supply to a biosimilar brand of adalimumab (Amgevita) from 1 February 2022. Consultation on the proposal opens today
We’re pleased to announce that dulaglutide (Trulicity), a GLP-1 agonist supplied by Eli Lilly, will be funded from 1 September 2021 for patients who meet certain eligibility criteria
Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management